Abstract

Nanobody (Nb) is a promising vector for targeted drug delivery. This study aims to identify an Nb that can specifically target the lung by binding human pulmonary surfactant protein A (SP-A). Human lung frozen tissue sections were used for 3 rounds of biospanning of our previously constructed Nb library for rat SP-A to establish a sub-library of Nb, which specifically bound human lung tissues. Phage-ELISA was performed to screen the sub-library to identify Nb4, which specifically bound human SP-A. The binding affinity Kd of Nb4 to recombinant human SP-A was 7.48 × 10−7 M. Nb4 (19 kDa) was stable at 30 °C–37 °C and pH 7.0–7.6 and specifically bound the SP-A in human lung tissue homogenates, human lung A549 cells, and human lung tissues, whereas didn’t react with human liver L-02 cells, kidney 293T cells, and human tissues from organs other than the lung. Nb4 accumulated in the lung of nude mice 5 minutes after a tail vein injection of Nb4 and was excreted 3 hours. Short-term exposure (one month) to Nb4 didn’t cause apparent liver and kidney toxicity in rats, whereas 3-month exposure resulted in mild liver and kidney injuries. Nb4 may be a promising vector to specifically deliver drugs to the lung.

Highlights

  • Nanobody (Nb) is a promising vector for targeted drug delivery

  • We developed an anti-surfactant protein A (SP-A) polyclonal antibody-conjugated dexamethasone liposome, which showed a higher localized and specific accumulation in the lung and superior efficacy to attenuate lung injury than free dexamethasone in a rat model of bleomycin-induced lung injury[4]

  • Human lung tissues expressed abundant SP-A protein, which appeared as protein bands with molecular weights of 35 kDa and 70 kDa on the SDS-PAGE gel (Fig. 1a)

Read more

Summary

Introduction

This study aims to identify an Nb that can target the lung by binding human pulmonary surfactant protein A (SP-A). Nb4 may be a promising vector to deliver drugs to the lung. We developed an anti-SP-A polyclonal antibody-conjugated dexamethasone liposome, which showed a higher localized and specific accumulation in the lung and superior efficacy to attenuate lung injury than free dexamethasone in a rat model of bleomycin-induced lung injury[4]. The anti-SP-A polyclonal antibody-conjugated dexamethasone liposome has a high molecular weight, and penetrates the target tissue poorly and shows long hepatic and splenic retention and strong immunogenicity, suggesting that anti-SP-A polyclonal antibody may not be an ideal pulmonary targeting vector. The current study aims to identify an anti-SP-A Nb that is specific to human lung tissues

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call